First, proteomics screening and statistical analysis show that blood biomarkers LGALS3BP, ACE, and POSTN effectively screen for cerebral amyloid depositions and clinically diagnose Alzheimer’s disease, but the theoretical basis is still lacking. Here, LGALS3BP is linked to Alzheimer disease.